Keyword: Profectus Biosciences
Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.
Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.
Officials have vaccinated about 3,200 individuals in the Democratic Republic of Congo in response to a deadly outbreak.
With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
Here is some other vaccine news of note for the week.